Target intelligence / Profile preview

Tenascin-N (TNN)

Target: TNN
Molecular classification: Extracellular matrix glycoprotein, Cell adhesion molecule, Ligand for integrins (specifically ITGA8:ITGB1, ITGAV:ITGB1, ITGA4:ITGB1), Tenascin family member

Overview

Tenascin-N is a large, modular extracellular matrix glycoprotein and a member of the tenascin family. It participates in cell adhesion, migration, and neurite outgrowth, acting as a ligand for several integrins. It promotes angiogenesis in tumors by facilitating endothelial cell elongation, migration and sprouting, and is notably expressed in breast cancer and metastatic bone niches, where it enhances tumorigenic cell migration and proliferation[3][4][6]. Tenascin-N can inhibit chondroblast proliferation during bone formation and is involved in cell-matrix interactions influencing development and disease. Its expression is linked to certain rare genetic syndromes and may serve as a prognostic marker in cancer. While it shares some homology and functions with other tenascin family proteins, Tenascin-N plays a distinctive role in tumor microenvironments and tissue-specific remodeling[3][4][6].

Other names: Tenascin-NTNNtenascin NTN-NTenascin-WTNWtenascin-WTN-W

Mechanism of action

Not applicable; no drugs with established mechanisms of action described for Tenascin-N.

Biological functions

Positive regulation of sprouting angiogenesisRegulation of cell adhesionRegulation of cell migrationPromotion of neurite outgrowthInhibition of chondroblast proliferation and differentiation during endochondral bone formation (via WNT signaling)

Disease associations

Cancer (e.g., breast cancer, metastatic niche in bone)Developmental disorders (e.g., Seckel syndrome, congenital generalized lipodystrophy type 1)Tissue remodeling

Safety considerations

No specific safety concerns documented for therapies targeting Tenascin-N, as no direct drugs exist. Targeting extracellular matrix proteins in general may impact tissue remodeling and physiological repair[3].

Biomarkers

Tenascin-N expression is a biomarker for certain tumors, such as breast cancer, where it may facilitate migratory behavior and angiogenesis[3][6].May be relevant for patient stratification in bone metastasis settings[6].

Beyond the preview

Go deeper on Tenascin-N (TNN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tenascin-N (TNN).

Explore the full profile